B+
Bull case
0%
Probability
Target price
$30.50
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
PFE
PfizerBNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
1%
Probability
Target price
$27.75
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
0%
Probability
Target price
$22.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+61.5
Score
AI commentary
T+3 sentiment is mildly positive but still monitoring-style. The primary-source earnings release was supportive, and trusted post-print coverage indicated the stock rose more than 2% early on May 5 after the beat/reaffirmation, but the tone was tempered by commentary that a fuller growth recovery may take several years. Analyst revision visibility remains thin in the checked evidence, and no usable social-coverage signal was provided, so confidence should remain moderate rather than high.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-20eventQ1 beat and full-year 2026 guidance reaffirmation reset the post-print baselineMedium impact
Pfizer's May 5 earnings release reported Q1 2026 revenue of $14.451B, adjusted EPS of $0.75, and reaffirmed 2026 guidance of $59.5B-$62.5B revenue and $2.80-$3.00 adjusted EPS, which supports a near-term stabilization case after the print [#8-K-2026-05-05].
2026-08-03catalystLaunched and acquired product growth is the key bridge through COVID erosion and the coming LOE gapHigh impact
Primary-source Q1 results showed 22% operational growth from launched and acquired products and 7% operational growth ex-Comirnaty/Paxlovid, led by Padcev, Eliquis, oncology biosimilars, Nurtec, Lorbrena and Abrysvo, partially offset by Comirnaty down 59% operationally and Paxlovid down 63% operationally [#8-K-2026-05-05].
2026-12-31catalystPipeline readouts and pivotal-study cadence remain the main medium-term rerating leverHigh impact
Pfizer's Q1 2026 earnings materials highlighted positive Phase 3 and mid-stage readouts, pipeline momentum in oncology and obesity, and a plan to start about 20 key pivotal studies in 2026, keeping development execution as the main medium-term upside lever even if revenue recovery is back-end loaded.
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology